Abstract | OBJECTIVES: To estimate the probability of response when intravesical bacille Calmette-Guérin (BCG) is given in combination with oral bropirimine for bladder carcinoma in situ, and to evaluate toxicity when the 2 agents are combined. METHODS: A total of 51 patients with histologic evidence of carcinoma in situ and no prior treatment with BCG or bropirimine were enrolled in a cooperative group multicenter phase II trial. Initial treatment included Tice BCG 50 mg weekly for 6 weeks and oral bropirimine 3.0 g/day for 3 consecutive days each week for 12 weeks. Response was assessed after 12 weeks by cystoscopy, biopsy, and barbotage cytology. Most patients received a second course followed by an identical assessment. Toxicity was recorded according to the Southwest Oncology Group toxicity criteria. RESULTS: A total of 51 patients were enrolled and treated. There were 42 patients who were eligible and valuable for response and toxicity. There were 28 complete responders (67%, 50% to 80% 95% confidence interval). The 5-year progression-free survival estimate is 53%, and the 5-year survival estimate is 80%. There were no deaths, 2 patients had grade 4 toxicity, 14 grade 3 toxicity, 17 grade 2 toxicity, 6 grade 1 toxicity, and only 3 had no toxicity reported as their worst toxicity grade. CONCLUSIONS: The combination failed to show an estimated response higher than 80%. It is not recommended that further evaluation of this combination be conducted.
|
Authors | Michael F Sarosdy, Catherine M Tangen, Geoffrey R Weiss, Blake R Nestok, Mitchell C Benson, Paul F Schellhammer, Arthur I Sagalowsky, David P Wood Jr, E David Crawford |
Journal | Urologic oncology
(Urol Oncol)
2005 Nov-Dec
Vol. 23
Issue 6
Pg. 386-9
ISSN: 1078-1439 [Print] United States |
PMID | 16301114
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- BCG Vaccine
- Cytosine
- bropirimine
|
Topics |
- Aged
- Aged, 80 and over
- BCG Vaccine
(therapeutic use)
- Carcinoma in Situ
(drug therapy, pathology)
- Cytosine
(administration & dosage, analogs & derivatives, pharmacology)
- Disease Progression
- Humans
- Medical Oncology
- Middle Aged
- Survival Rate
- United States
- Urinary Bladder Neoplasms
(drug therapy, pathology)
|